Stelic Institute & Co..

tin3.jpg

Chronology of Corporate News

Nov-2004
Founded as Stelic Corp. at Toranomon, MInato-city, Tokyo for commercializing Stem Cell Research.
Feb-2005
Established Research Facility at Oji kita-city,Tokyo
Oct-2005
Relocated Head Office to Higashi Azabu,Minato
Nov-2005
Organized the First Symposium on Regenerative Medicine (Tokyo)
Jun-2006
Relocated Research Facility to Higashi Azabu, Minato-city Tokyo Renamed Stelic Institute & Co.
Aug-2006
Organized Research Seminar at University of California, Irvine (Irvine, CA USA)
Nov-2006
Initiated Collaborative Research with Niigata University Graduate School of Medical and Dental Sciences
Jan-2007
Started Collaborative Research with University of California Irvine
Feb-2007
Organized the Second Symposium on Regenerative Medicine (Tokyo)
Mar-2007
Announced research results at the Keystone Symposia (USA)
May-2007
Initiated Collaborative Research with Department of Gastroenterology of Juntendo University School of Medicine
Feb-2008
Organized the Third Symposium on Regenerative Medicine (Tokyo)
Mar-2008
Stelic Announces Grant of New Patent Covering Medical Use of G-family Inhibitor for COPD (Chronic Obstructive Pulmonary Disease)
May-2008
Initiated Collaborative Research with Department of Clinical Pharmacology, Niigata University Graduate School of Health Sciences
Jun-2008
Stelic Announces Grant of New Patent CoveringMedical Use of G-family Inhibitor for CNS (Central Nervous System)
Jul-2008
Initiated Collaborative Research with Department of Clinical Pharmacology, Niigata University of Pharmacy and Applied Life Sciences
Aug-2008
Stelic Announces Grant for New Patent Covering Medical Use for Injured hepatocyte by anti-CXCL10 Antibody
Aug-2008
Received Grant from Kanto Bureau of Economy, Trade and Industry for Research
Aug-2009
Received grant from NEDO: “Grant for Application of Industrial Technology Innovation”.
Dec-2009
Received top grade grant from JST
Subject: “The development of RNA interference-based therapeutics for Crohn’s disease stricture.”
JST; Japan Science and Technology Agency
Aug-2011
Received approval of first-in-patient, Phase 1 clinical trial application of STNM01 for Crohn’s disease patients in Japan.
July-2012
Completed Phase 1 study for Crohn’s disease in Japan.
June-2013
Received approval of Phase 2a clinical trial application of STNM01 for the treatment of Ulcerative Colitis in Germany.
May-2014
Presented Phase 1 clinical results for Crohn’s disease at DDW Chicago.
June-2014
Received approval of IIT for the treatment of drug-refractory, unresectable pancreatic cancer.
May-2015
Presented IIT interim results for the treatment of drug-refractory, unresectable pancreatic cancer at DDW Washington DC.
June-2015
Presented IIT interim results for the treatment of drug-refractory, unresectable pancreatic cancer at ASCO Chicago.
Oct-2015
Presented IIT interim results for the treatment of drug-refractory, unresectable pancreatic cancer at UEGW Barcelona.
Jan-2016
Received approval of IIT for the treatment of drug-refractory, severe Crohn’s disease.
Jan-2016
Received approval of IIT for the treatment of drug-refractory, severe Ulcerative Colitis.
May-2016
Presented nonclinical results of oral siRNA drug for the treatment of colitis at DDW SanDiego.
May-2016
Presented IIT results for the treatment of drug-refractory, unresectable pancreatic cancer at DDW SanDiego.
July-2016
Completed Phase 2a study for the treatment of moderate-to-severe Ulcerative Colitis in Germany.

ページの先頭へ